Brian Silver
Director/Board Member chez Novalgen Ltd.
Fortune : 261 107 $ au 31/03/2024
Profil
Brian Michael Silver is a professional with experience in investment banking, law, and corporate finance.
He is currently a Non-Executive Director at Novalgen Ltd.
He previously worked as MD-HealthCare Investment Banking Group at Morgan Stanley from 1998 to 2013, an Associate at Sullivan & Cromwell LLP from 1994 to 1997, Head-Biotechnology & Partner at Perella Weinberg Partners from 2013 to 2018, CFO & Head-Corporate Development at Freeline Therapeutics Holdings Plc from 2018 to 2021, and Chief Financial Officer & Treasurer at TScan Therapeutics, Inc. from 2021 to 2023.
Mr. Silver holds a graduate degree from The University of Chicago Law School and an undergraduate degree from Harvard College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TSCAN THERAPEUTICS, INC.
0,08% | 13/06/2023 | 32 885 ( 0,08% ) | 261 107 $ | 31/03/2024 |
Postes actifs de Brian Silver
| Sociétés | Poste | Début |
|---|---|---|
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Director/Board Member | - |
Anciens postes connus de Brian Silver
| Sociétés | Poste | Fin |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Director of Finance/CFO | 21/07/2023 |
| FREELINE THERAPEUTICS HOLDINGS PLC | Director of Finance/CFO | 30/04/2021 |
| PERELLA WEINBERG PARTNERS | Corporate Officer/Principal | 01/11/2018 |
| MORGAN STANLEY | Corporate Officer/Principal | 01/07/2013 |
Sullivan & Cromwell LLP
 Sullivan & Cromwell LLP Miscellaneous Commercial ServicesCommercial Services Sullivan & Cromwell LLP provides legal services. It specializes in the areas of corporate law, securities, corporate, litigation, mergers, real estate, pro bono, investment management and taxation. Their clients include industrial, commercial, financial, private funds, governmental, educational, charitable and cultural enterprises and entities. The company was founded by Algernon Sydney Sullivan and William Nelson Cromwell in 1879 and is headquartered in New York City, NY. | Corporate Officer/Principal | 01/01/1997 |
Formation de Brian Silver
| The University of Chicago Law School | Graduate Degree |
| Harvard College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MORGAN STANLEY | Finance |
| TSCAN THERAPEUTICS, INC. | Health Technology |
| PERELLA WEINBERG PARTNERS | Finance |
| Entreprise privées | 3 |
|---|---|
Sullivan & Cromwell LLP
Sullivan & Cromwell LLP Miscellaneous Commercial ServicesCommercial Services Sullivan & Cromwell LLP provides legal services. It specializes in the areas of corporate law, securities, corporate, litigation, mergers, real estate, pro bono, investment management and taxation. Their clients include industrial, commercial, financial, private funds, governmental, educational, charitable and cultural enterprises and entities. The company was founded by Algernon Sydney Sullivan and William Nelson Cromwell in 1879 and is headquartered in New York City, NY. | Commercial Services |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
